Effective control of Epstein-Barr virus infection following pediatric liver transplantation by monitoring of viral DNA load and lymphocyte surface markers

Pediatric Transplantation

Volumn 16, Issue 7, 2012, Pages 748-757

  Imadome, Ken Ichi ^a   Fukuda, Akinari ^b   Kawano, Fuyuko ^a   Imai, Yumi ^a   Ichikawa, Sayumi ^a   Mochizuki, Masashi ^a   Shigeta, Takanobu ^b   Kakiuchi, Toshihiko ^b   Sakamoto, Seisuke ^b   Kasahara, Mureo ^b   Fujiwara, Shigeyoshi ^a  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Epstein Barr virus; flow cytometry; liver transplantation; LMP2; lymphoproliferative disorder; real time PCR; tetramer

Indexed keywords

ACICLOVIR; CD19 ANTIBODY; CD23 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; HLA DR ANTIGEN; LATENT MEMBRANE PROTEIN 2; LYMPHOCYTE SURFACE MARKER; TACROLIMUS; VIRUS DNA;

ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; ANTIBODY TITER; ARTICLE; BILE DUCT ATRESIA; CARBAMYL SYNTHASE 1 DEFICIENCY; CD19+ CD23+ T LYMPHOCYTE; CD4 CD8 RATIO; CHILD; CYTOMEGALOVIRUS ANTIGENEMIA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FLOW CYTOMETRY; FULMINANT HEPATIC FAILURE; GENE EXPRESSION; GLYCOGEN STORAGE DISEASE 1B; GRAFT RECIPIENT; GRAFT REJECTION; HERPES SIMPLEX; HUMAN; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; LIVER DISEASE; LIVER TRANSPLANTATION; LIVING DONOR; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; METHYLMALONEMIA; MOLECULAR DIAGNOSIS; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; PATIENT MONITORING; PEDIATRIC SURGERY; PORTAL VENOUS SYSTEM ANOMALY; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SEROLOGY; T LYMPHOCYTE; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIGENS, CD19; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; INFANT, NEWBORN; LIVER FAILURE; LIVER TRANSPLANTATION; LYMPHOCYTES; RECEPTORS, IGE; TACROLIMUS; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 84866730279     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2012.01750.x     Document Type: Article

References (34)

1. Rickinson AB, Kieff ED,. Epstein-Barr virus. In:, Knipe DM, Howley PM, eds. Fields Virology, 5th edn. Philadelphia: Lippincott Williams and Wilkins, 2007: pp. 2655-2700.
2. Hislop AD, Taylor GS, Sauce D, Rickinson AB,. Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. Annu Rev Immunol 2007: 25: 587-617.
3. Paya CV, Fung JJ, Nalesnik MA, et al., Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999: 68: 1517-1525.
4. Nourse JP, Jones K, Gandhi MK,. Epstein-barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy. Am J Transplant 2011: 11: 888-895.
5. Timms JM, Bell A, Flavell JR, et al., Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: Similarities to EBV-positive Hodgkin's lymphoma. Lancet 2003: 361: 217-223.
6. D'Alessandro AM, Knechtle SJ, Chin LT, et al., Liver transplantation in pediatric patients: Twenty years of experience at the University of Wisconsin. Pediatr Transplant 2007: 11: 661-670.
7. Leblond V, Choquet S,. Lymphoproliferative disorders after liver transplantation. J Hepatol 2004: 40: 728-735.
8. Newell KA, Alonso EM, Whitington PF, et al., Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996: 62: 370-375.
9. Allen UD, Farkas G, Hebert D, et al., Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: A case-control study. Pediatr Transplant 2005: 9: 450-455.
10. Holmes RD, Sokol RJ,. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002: 6: 456-464.
11. Opelz G, Daniel V, Naujokat C, Dohler B,. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009: 88: 962-967.
12. Cacciarelli TV, Reyes J, Jaffe R, et al., Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant 2001: 5: 359-364.
13. Fernandez MC, Bes D, De Davila M, et al., Post-transplant lymphoproliferative disorder after pediatric liver transplantation: Characteristics and outcome. Pediatr Transplant 2009: 13: 307-310.
14. Stevens SJ, Verschuuren EA, Pronk I, et al., Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001: 97: 1165-1171.
15. Lee TC, Savoldo B, Rooney CM, et al., Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005: 5: 2222-2228.
16. Rowe DT, Qu L, Reyes J, et al., Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997: 35: 1612-1615.
17. Van Esser JW, Van Der Holt B, Meijer E, et al., Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell - depleted SCT. Blood 2001: 98: 972-978.
18. Kimura H, Morita M, Yabuta Y, et al., Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999: 37: 132-136.
19. Nakamura H, Iwakiri D, Ono Y, Fujiwara S,. Epstein-Barr-virus-infected human T-cell line with a unique pattern of viral-gene expression. Int J Cancer 1998: 76: 587-594.
20. Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ,. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 2002: 74: 367-372.
21. Gregorek H, Jankowska I, Dzierzanowska-Fangrat K, et al., Long-term monitoring of Epstein-Barr virus DNA load and humoral parameter abnormalities in pediatric liver transplant recipients before development of malignancy. Pediatr Transplant 2010: 14: 629-635.
22. Axelrod DA, Holmes R, Thomas SE, Magee JC,. Limitations of EBV-PCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder. Pediatr Transplant 2003: 7: 223-227.
23. Schaffer K, Hassan J, Staines A, et al., Surveillance of EBV viral loads in adult liver transplantation: Association with age, gender, time post-transplant and transplant indication. Liver Transpl 2011: 17: 1420-1426.
24. Pageaux GP, Bonnardet A, Picot MC, et al., Prevalence of monoclonal immunoglobulins after liver transplantation: Relationship with posttransplant lymphoproliferative disorders. Transplantation 1998: 65: 397-400.
25. Rosselet A, Vu DH, Meylan P, et al., Associations of serum EBV DNA and gammopathy with post-transplant lymphoproliferative disease. Clin Transplant 2009: 23: 74-82.
26. Meij P, Van Esser JW, Niesters HG, et al., Impaired recovery of Epstein-Barr virus (EBV) - specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003: 101: 4290-4297.
27. Annels NE, Kalpoe JS, Bredius RG, et al., Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006: 42: 1743-1748.
28. Clave E, Agbalika F, Bajzik V, et al., Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: Relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004: 77: 76-84.
29. Sebelin-Wulf K, Nguyen TD, Oertel S, et al., Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol 2007: 17: 203-210.
30. Bingler MA, Feingold B, Miller SA, et al., Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 2008: 8: 442-445.
31. Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G,. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant 2009: 13: 319-323.
32. D'antiga L, Del Rizzo M, Mengoli C, Cillo U, Guariso G, Zancan L,. Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transpl 2007: 13: 343-348.
33. Macedo C, Webber SA, Donnenberg AD, et al., EBV-specific CD8+ T cells from asymptomatic pediatric thoracic transplant patients carrying chronic high EBV loads display contrasting features: Activated phenotype and exhausted function. J Immunol 2011: 186: 5854-5862.
34. Takeuchi K, Tanaka-Taya K, Kazuyama Y, et al., Prevalence of Epstein-Barr virus in Japan: Trends and future prediction. Pathol Int 2006: 56: 112-116.